Brookfield Corp’s ALX Oncology ALXO Stock Holding History

Brookfield Corp’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,646	Closed	-$491K	–	625
2021 Q3	$491K	Buy	+6,646	New	+$443K	﹤0.01%	473

Other funds holding ALXO

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Brookfield Corp's ALXO Position: Q4 2021 in Review

Brookfield Corp sold out of ALX Oncology (ALXO) in Q4 2021, closing a stake of 6,646 shares — an estimated $491K sold.

Brookfield Corp first reported a position in ALXO in Q3 2021 and held it in 1 quarter. The position peaked at $491K in Q3 2021. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

Brookfield Corp reported no remaining ALX Oncology position as of Q4 2021 after selling out during the quarter.
Brookfield Corp sold 6,646 ALX Oncology shares in Q4 2021, an estimated $491K.
Brookfield Corp first reported a position in ALX Oncology in Q3 2021 and held it in 1 quarter.
Brookfield Corp's ALX Oncology position peaked at $491K in Q3 2021.
108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on Brookfield Corp's 13F filing for Q4 2021, filed 14 Feb 2022.